Deng Xiao-Wei, Xie Ning
Zhongguo Zhong Yao Za Zhi. 2014 Apr;39(8):1374-8.
Berberine is the major component of Coptidis Rhizoma and it has been used as anti-infection, anti-inflammation drug for gastrointestinal diseases. In recent years, evidence showed that it could regulate glucose and lipid metabolism. Moreover, its activity had been tested by clinical trials and animal researches. The mechanisms of berberine in diabetes include: improving the function of beta-cell; prompting insulin secretion and islets regeneration, lowing lipid level, regulating glucose and lipid metabolic by influence transcriptional factors expression such as PPARgamma, C/EBPalpha, SREBP-1c, LXR, having the activities of anti-oxidation and inhibiting reductase to repress oxidative stress state and regulate metabolic signal pathway. Although numbers of data supported that berberine could improving insulin resistance by clinical trials and animal studies, the large scale, multicenter clinical trials are needed to evaluate the effects of berberine for diabetes and its complications in the time of evidence-based medicine.
黄连素是黄连的主要成分,一直被用作治疗胃肠道疾病的抗感染、抗炎药物。近年来,有证据表明它可以调节糖脂代谢。此外,其活性已通过临床试验和动物研究得到验证。黄连素治疗糖尿病的机制包括:改善β细胞功能;促进胰岛素分泌和胰岛再生,降低血脂水平,通过影响PPARγ、C/EBPα、SREBP-1c、LXR等转录因子的表达来调节糖脂代谢,具有抗氧化活性并抑制还原酶以抑制氧化应激状态并调节代谢信号通路。尽管大量数据通过临床试验和动物研究支持黄连素可以改善胰岛素抵抗,但在循证医学时代,仍需要大规模、多中心的临床试验来评估黄连素对糖尿病及其并发症的影响。